NO20040794L - (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor. - Google Patents

(-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.

Info

Publication number
NO20040794L
NO20040794L NO20040794A NO20040794A NO20040794L NO 20040794 L NO20040794 L NO 20040794L NO 20040794 A NO20040794 A NO 20040794A NO 20040794 A NO20040794 A NO 20040794A NO 20040794 L NO20040794 L NO 20040794L
Authority
NO
Norway
Prior art keywords
azabicyclo
dichlorophenyl
hexane
compounds
reuptake inhibitor
Prior art date
Application number
NO20040794A
Other languages
English (en)
Other versions
NO327424B1 (no
Inventor
Joseph Williams Epstein
Arnold Stan Lippa
Original Assignee
Dov Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dov Pharmaceutical Inc filed Critical Dov Pharmaceutical Inc
Publication of NO20040794L publication Critical patent/NO20040794L/no
Publication of NO327424B1 publication Critical patent/NO327424B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
NO20040794A 2001-08-24 2004-02-23 (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, fremgangsmater for dets fremstilling, sammensetninger samt nevnte forbindelse for behandling eller forebygging av naermere definerte lidelser NO327424B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/939,071 US6569887B2 (en) 2001-08-24 2001-08-24 (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
PCT/US2002/025870 WO2003017927A2 (en) 2001-08-24 2002-08-14 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

Publications (2)

Publication Number Publication Date
NO20040794L true NO20040794L (no) 2004-05-17
NO327424B1 NO327424B1 (no) 2009-06-29

Family

ID=25472498

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040794A NO327424B1 (no) 2001-08-24 2004-02-23 (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, fremgangsmater for dets fremstilling, sammensetninger samt nevnte forbindelse for behandling eller forebygging av naermere definerte lidelser

Country Status (21)

Country Link
US (6) US6569887B2 (no)
EP (1) EP1427411B1 (no)
JP (1) JP2005504049A (no)
KR (1) KR20040065549A (no)
CN (2) CN101050199A (no)
AT (1) ATE355838T1 (no)
BR (1) BR0212147A (no)
CA (1) CA2458217A1 (no)
DE (1) DE60218703T2 (no)
DK (1) DK1427411T3 (no)
ES (1) ES2284968T3 (no)
HU (1) HUP0401515A2 (no)
IL (1) IL160545A0 (no)
MX (1) MXPA04001643A (no)
NO (1) NO327424B1 (no)
NZ (1) NZ531606A (no)
PL (1) PL368601A1 (no)
PT (1) PT1427411E (no)
RU (1) RU2300522C2 (no)
WO (1) WO2003017927A2 (no)
ZA (1) ZA200401545B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
US20050282859A1 (en) * 2004-06-04 2005-12-22 Thor Karl B Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders
MX2007000851A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
RU2007102292A (ru) * 2004-07-22 2008-08-27 Вайет (Us) Способ лечения расстройств и заболеваний нервной системы
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
US20110015246A2 (en) * 2005-03-14 2011-01-20 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
NZ561677A (en) * 2005-04-04 2011-02-25 Takeda Pharmaceutical (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, and its use for treating depression and anxiety neurosis
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
NZ592836A (en) * 2005-07-27 2013-01-25 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
BRPI0716532A2 (pt) * 2006-09-11 2013-09-24 Glaxo Group Ltd compostos azabicÍclios como inidores de reabsorÇço de monoaminas
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
GB0625198D0 (en) 2006-12-18 2007-01-24 Glaxo Group Ltd Chemical compounds
DK2354124T3 (da) * 2006-12-19 2013-03-11 Hoffmann La Roche Heteroarylpyrrolidinyl og piperidinylketonderivater
AU2008245836A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-E-10-OH-NT and methods for their synthesis and use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
AU2009259492A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Aryl ketone as MRI
BR112012000657A2 (pt) 2009-06-26 2016-11-16 Panacea Biotec Ltd novos azabicilohexanos
CN102417475A (zh) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用
PT2819516T (pt) * 2011-07-30 2020-03-25 Otsuka America Pharmaceutical Inc Utilização de (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciclo[3.1.0]hexano no tratamento de doenças afectadas por neurotransmissores monoaminas
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US411839A (en) * 1889-10-01 Machine for grinding and polishing road scraper blades
BE800903A (fr) 1973-06-14 1973-12-14 Babitsky Boris D Procede d'obtention de polymeres d'alcoyl-2 butadienes-1,3 ou de copolymeres d'alcoyl-2 butadienes-1,3-butadiene-1,3
US3892772A (en) 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
JPS535994B2 (no) 1974-09-26 1978-03-03
US4088652A (en) 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4231935A (en) 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4131611A (en) 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4196120A (en) 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
US4183857A (en) * 1978-07-06 1980-01-15 Shell Oil Company 3-Benzyl-3-azabicyclo(3.1.0)hexane-2,4-dione
GB1532682A (en) 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
US4118417A (en) 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
GR72713B (no) 1976-09-15 1983-12-01 American Cyanamid Co
US4118393A (en) 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
IL65843A (en) 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CH644580A5 (de) 1980-01-29 1984-08-15 Hoffmann La Roche Cyclohexen-derivate.
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3324263A1 (de) 1983-07-06 1985-01-17 Hoechst Ag, 6230 Frankfurt Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
AU7077894A (en) * 1993-07-02 1995-01-24 University Of Nottingham, The Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5488056A (en) 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
KR100389518B1 (ko) 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US5911992A (en) 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
US6121261A (en) 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
US6245911B1 (en) 1997-12-05 2001-06-12 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
US6497631B1 (en) 1999-09-15 2002-12-24 Wilson Sporting Goods Co. Ball bat
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US6569887B2 (en) 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20040127541A1 (en) 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
PL376604A1 (pl) 2002-11-08 2006-01-09 Dov Pharmaceuticals, Inc. Polimorfy chlorowodorku bicifadyny

Also Published As

Publication number Publication date
ES2284968T3 (es) 2007-11-16
NO327424B1 (no) 2009-06-29
CN101050199A (zh) 2007-10-10
WO2003017927A3 (en) 2003-04-17
EP1427411B1 (en) 2007-03-07
US20030045567A1 (en) 2003-03-06
EP1427411A2 (en) 2004-06-16
CN1575170A (zh) 2005-02-02
NZ531606A (en) 2005-08-26
RU2300522C2 (ru) 2007-06-10
US20070082938A1 (en) 2007-04-12
US6716868B2 (en) 2004-04-06
DE60218703D1 (de) 2007-04-19
US7041835B2 (en) 2006-05-09
WO2003017927A2 (en) 2003-03-06
DK1427411T3 (da) 2007-07-02
KR20040065549A (ko) 2004-07-22
US20040157869A1 (en) 2004-08-12
US6569887B2 (en) 2003-05-27
RU2004108694A (ru) 2005-03-10
ATE355838T1 (de) 2007-03-15
EP1427411A4 (en) 2005-04-20
CA2458217A1 (en) 2003-03-06
IL160545A0 (en) 2004-07-25
HUP0401515A2 (hu) 2004-12-28
PL368601A1 (en) 2005-04-04
DE60218703T2 (de) 2007-12-06
US20030181508A1 (en) 2003-09-25
ZA200401545B (en) 2005-03-10
US20040157908A1 (en) 2004-08-12
BR0212147A (pt) 2004-08-24
US20040157870A1 (en) 2004-08-12
JP2005504049A (ja) 2005-02-10
US7098230B2 (en) 2006-08-29
PT1427411E (pt) 2007-06-15
US7081471B2 (en) 2006-07-25
MXPA04001643A (es) 2004-05-31

Similar Documents

Publication Publication Date Title
NO20040794L (no) (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.
GEP20063894B (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
HRP20090195T1 (hr) Inhibitori mitotičkih kinezina
MXPA05009367A (es) Antagonistas del receptor opioide.
MY140236A (en) Diarylether compounds useful as opioid receptor antagonists
TW200510277A (en) Crystalline form of β2-adrenergic receptor agonist
GEP20074133B (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
CZ305838B6 (cs) N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
WO2004043920A8 (en) Polymorphs of bicifadine hydrochloride
NO20071372L (no) Nye polymorfer av azabisykloheksan
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
MXPA04005305A (es) Nuevo polimorfo cristalino de clorhidrato de venlafaxina y metodos para preparacion del mismo.
IL153784A0 (en) Novel n-(2-phenyl-3-aminopropyl) naphthamides
EP1406614A4 (en) CARVEDILOLPOLYMORPH
DK1335922T3 (da) Fremgangsmåde til fremstilling af 4'-demethyl-4'-O-substituerede 1-deoxypodophyllotoxinderivater og geometriske isomerer deraf og anticancersammensætninger, der indeholder samme
EP1567508A4 (en) 1,2,4-TRIAZOLE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
DE60235119D1 (en) Bipyridinylderivate als hochselektive cyclooxygenase-2-inhibitoren
MX2007004400A (es) Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida.
NO20030876D0 (no) Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin
BG106959A (en) Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl] cyclohexanecarboxylate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees